Recent Advances in the Management of Non-Melanoma Skin Cancers

Dr Khushalani defines cutaneous squamous cell carcinoma (cSCC), reviews the risk factors associated, and explains the staging system for patients diagnosed with cSCC.

An overview of treatment options for patients for with cSCC, focusing on the neoadjuvant setting.

Glenn J Hanna, MD, provides a brief overview of cutaneous squamous cell carcinoma (cSCC), and discusses the currently available treatment options for patients with advanced cSCC.

Dr Hanna comments on updated efficacy and safety data of the EMPOWER-CSCC-1 trial that was recently discussed at the annual ESMO and ASCO 2022 meetings.

Nikhil Khushalani, MD, comments on updated data evaluating the use of cemiplimab in the neoadjuvant setting for patients with cSCC.

Dr Khushalani provides insights into real-world data that was recently discussed at ESMO 2022 assessing the use of cemiplimab in patients with advanced cSCC.

Dr Hanna highlights investigational agents that are being studied for the treatment of advanced cSCC and discuss some unmet needs for cSCC.

Dr Hanna defines basal cell carcinoma (BCC), reviews current treatment options and explains the role of cemiplimab for the treatment of advanced BCC.

Dr Khushalani discusses challenges faced when treating patients with cSCC and shares advice for fellow colleagues who treat patients with cSCC.

An expert provides a brief overview of basal cell carcinoma (BCC) and reviews currently available treatment options for patients with BCC.

Nikhil Khushalani, MD, comments on upcoming treatment advances he looks forward to for patients with BCC.